Mikart, LLC, a US-based Contract Development and Manufacturing Organisation (CDMO), announced on Thursday that it has added Fette double-sided tablet presses to increase its production capacity and meet the product demands of its increasing number of customers.
The tablet presses have advanced features, which include automatic weight control, metal detectors, dedusters and bulk powder feeding systems for optimal efficiency and precision of tablet production applications.
Michael Kallelis, Mikart, LLC CEO, said, 'We are thrilled to expand our Fette tablet press platforms into our manufacturing operations. These high-speed and high-volume presses mark a significant milestone in our journey towards enhancing client satisfaction and accommodating the growing brand and generic market.'
Hikma Pharmaceuticals extends KLOXXADO nasal spray shelf-life 8mg from 24 to 36 months
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
Emmaus Life Sciences names new chief executive officer
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)